Saruparib (AZD5305)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Saruparib (AZD5305), covering 2026-04-14 to 2026-04-14. Get the full timeline:
Most recent: Clinical Trial Update: Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer [Phase 3]